2011
Statin Use in Outpatients With Obstructive Coronary Artery Disease
Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin Use in Outpatients With Obstructive Coronary Artery Disease. Circulation 2011, 124: 2405-2410. PMID: 22064595, PMCID: PMC3527107, DOI: 10.1161/circulationaha.111.038265.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArterial Occlusive DiseasesCardiovascular DiseasesCholesterol, LDLCoronary Artery DiseaseFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedOutpatientsPractice Guidelines as TopicProspective StudiesRegistriesRetrospective StudiesRisk FactorsTreatment OutcomeConceptsObstructive coronary artery diseaseLow-density lipoprotein cholesterol levelsCoronary artery diseaseLipoprotein cholesterol levelsLipid-lowering therapyCholesterol levelsStatin therapyUntreated patientsStatin treatmentArtery diseaseLow-density lipoprotein cholesterol valuesNonstatin lipid-lowering medicationsRobust clinical trial evidenceRecent coronary revascularizationClinical trial evidenceLipid-lowering medicationsRoutine outpatient careLipoprotein cholesterol valuesRate of treatmentNonstatin medicationsNonstatin therapiesOutpatient registryCardiovascular morbidityCoronary revascularizationLipid management
2006
Influenza Vaccination as Secondary Prevention for Cardiovascular Disease
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease. Circulation 2006, 114: 1549-1553. PMID: 16982936, DOI: 10.1161/circulationaha.106.178242.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseSecondary preventionCardiovascular conditionsInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineHeart AssociationAnnual vaccinationVascular diseaseClinical trialsAmerican CollegeCardiology practiceAttenuated vaccinesInfluenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology. Journal Of The American College Of Cardiology 2006, 48: 1498-1502. PMID: 17010820, DOI: 10.1016/j.jacc.2006.09.004.Peer-Reviewed Original ResearchConceptsSecondary preventionCardiovascular diseaseCardiovascular conditionsAmerican CollegeAmerican Heart Association/American CollegeInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineScience AdvisoryHeart AssociationAnnual vaccinationVascular diseaseClinical trialsIncrease in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors